We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A sponsor of drug-device combination trials failed to submit IND applications, get signed investigator statements and select monitors before beginning the studies, according to an FDA warning letter.